""We've got to get better," Hardy said, emphasizing the need for improved diagnosis and political will alongside effective drugs to enhance Alzheimer's treatment."
""But now, finally, we've got somewhere," Hardy expressed his cautious optimism about the progress made in Alzheimer's research and treatment development."
""The problem: It hasn't stopped the disease, it's slowed it," Hardy noted regarding the limitations of current Alzheimer's treatments like Lecanemab."
Alzheimer's research is progressing with new treatments reaching patients, but effective diagnosis and political will are crucial for improvement. John Hardy emphasized the importance of better drugs and the need to address amyloid deposits in the brain. His earlier work identified amyloid's role in Alzheimer's, leading to the development of antibodies. Recent drugs like Donanemab and Lecanemab can remove existing amyloid deposits, but they only slow cognitive decline rather than stop the disease. Alzheimer's typically progresses over eight to nine years.
Read at WIRED
Unable to calculate read time
Collection
[
|
...
]